UncleBuck
Well-Known Member
and now for some real news to wash out the ugly taste of that right wing nonsense:
https://www.washingtonpost.com/blog...am-confirms-cnn-story/?utm_term=.29ff4020e3d9
Citing House records, CNN’s Raju earlier this week reported that last March, Price bought $1,001 to $15,000 worth of shares in Zimmer Biomet, a medical device company specializing in knee and hip implants. The purchase was followed less than a week later by Price’s introduction of the Healthy Inpatient Procedures (HIP) Act, which would delay implementation of a regulation affecting companies such as Zimmer Biomet.
And here’s the money-in-politics kicker to this story: After Price introduced the regulation-delaying bill, his reelection campaign received a contribution from the medical company’s political action committee.
When was the last time that a retraction request so thoroughly confirmed a story? Far from a retraction-worthy effort, Raju’s work profiles as a model of careful and measured journalism. According to an email chain provided by CNN, Raju pressed Blando in an email that laid out every material detail, including a timeline of Price’s purchase of Zimmer Biomet shares; his subsequent introduction of the regulation-delaying legislation; his attempt in 2015 to influence the Centers for Medicare and Medicaid Services (CMS) on this regulation; the fact that Zimmer Biomet would take a big hit from the regulation; and the matter of the campaign donation.
https://www.washingtonpost.com/blog...am-confirms-cnn-story/?utm_term=.29ff4020e3d9
Citing House records, CNN’s Raju earlier this week reported that last March, Price bought $1,001 to $15,000 worth of shares in Zimmer Biomet, a medical device company specializing in knee and hip implants. The purchase was followed less than a week later by Price’s introduction of the Healthy Inpatient Procedures (HIP) Act, which would delay implementation of a regulation affecting companies such as Zimmer Biomet.
And here’s the money-in-politics kicker to this story: After Price introduced the regulation-delaying bill, his reelection campaign received a contribution from the medical company’s political action committee.
When was the last time that a retraction request so thoroughly confirmed a story? Far from a retraction-worthy effort, Raju’s work profiles as a model of careful and measured journalism. According to an email chain provided by CNN, Raju pressed Blando in an email that laid out every material detail, including a timeline of Price’s purchase of Zimmer Biomet shares; his subsequent introduction of the regulation-delaying legislation; his attempt in 2015 to influence the Centers for Medicare and Medicaid Services (CMS) on this regulation; the fact that Zimmer Biomet would take a big hit from the regulation; and the matter of the campaign donation.
